Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
GOVX ON CNN!!>>Posted by: nikoli101
In reply to: None Date:3/11/2007 2:29:00 PM
Post #of 356
Just passing this along. As Sgr. Schultz would say, "I know nothinggg"
By: doctorduff
11 Mar 2007, 01:51 PM EDT
Msg. 1714 of 1715
Jump to msg. #
Geovax to be on CNN today Sunday, 3/11!
http://ragingbull.quote.com/mboard/boards.cgi?board=GOVX&read=1714
GOVX ON CNN!!>>Posted by: nikoli101
In reply to: None Date:3/11/2007 2:29:00 PM
Post #of 356
Just passing this along. As Sgr. Schultz would say, "I know nothinggg"
By: doctorduff
11 Mar 2007, 01:51 PM EDT
Msg. 1714 of 1715
Jump to msg. #
Geovax to be on CNN today Sunday, 3/11!
http://ragingbull.quote.com/mboard/boards.cgi?board=GOVX&read=1714
Test if stock is restricted by doing a small trade in your account after/before hours. If it happens during hours always have a phone close and be quick and sure.
Thanx Blue-It's on Super Scan Radar.
GOVX Getting alot of attention.
GOVX-AIDS Vaccine Nearing Reality>
Emory University researchers working on a vaccine for the AIDS virus
Web Editor: Keith Whitney
Last Modified: 3/8/2007 7:49:17 AM
The world could have a new vaccine designed to kill the AIDS virus in as little as three to four years according to an Atlanta-based group working on the vaccine.
It is a scientific advance that could save tens of millions of lives, and it is being developed on the campus of Emory University.
The work has been going on quietly for the last 15 years. But now it appears headed for the bell lap in the race to prevent the disease.
And the Atlanta-based group may be way ahead of the rest of the world.
The GeoVax lab at Emory is smaller than many garages. And yet the small modular building may be where the battle to end the reign of one the world's biggest killers could be won with a vaccine to prevent AIDS.
"We're getting results back that indicate we're getting very strong immune responses in these individuals these people who received our vaccine," said Don Hildebrand, the president and CEO of GeoVax Inc., the company spearheading the research in collaboration with Emory, the Centers for Disease Control, and the National Institutes of Health.
The vaccine uses a decoy virus with some of the genetic material of the aids virus but not enough for anyone to ever get the disease itself from the shot, according to Dr. Harriet Robinson, Ph. D., of the Emory Vaccine Center.
"It exposes your immune system to a pathogen like a virus or bacteria so before you've seen it you set up memory cells,” Dr. Robinson said, “and then these memory cells mobilize should you get the actual infection."
The test trials have been so successful that the vaccine is now more than a year ahead of schedule.
"Actually another two trials are starting later this year using different combinations of our vaccine and different administration programs,” said GeoVax CEO Hildebrand. “And following that presuming everything goes well we'll be starting a phase two program at the end of the year."
The vaccine works using a one-two pharmaceutical punch to prime the body then kill the virus.
“It raises both antibodies that can block the virus and it raises white blood cells called t cells that can kill the virus infected cells,” said Dr. Robinson. “So it really has two methods of controlling an HIV/AIDS infection once it enters the body."
The vaccine’s success with the simian AIDS virus has been nothing short of remarkable. Not only did the vaccine prevent the infection, it kept it under control for the monkeys that already had it, putting it in a kind of remission.
Researchers believe the same benefits await human subjects.
It"s way out of hand now.
Order a million of GOVX mon morning then.lol
GOVX Scottrade mabe others have restrictions on now. Heaven Forbid it started going up with good volume-they can"t have that. It"s now a common occurance for them to pull this crap.
Others doing it more and more too.
When a stock starts moving up strongly,Scottrade slaps restictions. F@%# them! But ST isn"t the only one now doing it.
GOVX Scottrade put Buy restrictions on-Friday.
LOL.
GOVX Scottrade put Buy restrictions on-Friday.
That"s Video is really Very Incredable.
LOL! Yes Sir. GOVX Goona be Big Topic this weekend.
Gap over 40 and ZOOOOOOOOOM!
Yup, And When GOVX Breaks .40-KABOOOM
This is getting in the news across the country at all levels!
Bet GOVX Gets to market Faster than People think.
GOVX Getting On News Across the Country! DRUDGE TOO!
Yes, Next week should be Big For GOVX.
GOVX Getting On News Across the Country! DRUDGE TOO!
GOVX Getting On News Across the Country! DRUDGE TOO!
GOVX: HUGE>
AIDS Vaccine Nearing Reality at Emory (GOVX)
Keith Whitney reports
Emory University researchers working on a vaccine for the AIDS virus
Web Editor: Keith Whitney
Last Modified: 3/8/2007 7:49:17 AM
The world could have a new vaccine designed to kill the AIDS virus in as little as three to four years according to an Atlanta-based group working on the vaccine.
It is a scientific advance that could save tens of millions of lives, and it is being developed on the campus of Emory University.
The work has been going on quietly for the last 15 years. But now it appears headed for the bell lap in the race to prevent the disease.
And the Atlanta-based group may be way ahead of the rest of the world.
The GeoVax lab at Emory is smaller than many garages. And yet the small modular building may be where the battle to end the reign of one the world's biggest killers could be won with a vaccine to prevent AIDS.
"We're getting results back that indicate we're getting very strong immune responses in these individuals these people who received our vaccine," said Don Hildebrand, the president and CEO of GeoVax Inc., the company spearheading the research in collaboration with Emory, the Centers for Disease Control, and the National Institutes of Health.
The vaccine uses a decoy virus with some of the genetic material of the aids virus but not enough for anyone to ever get the disease itself from the shot, according to Dr. Harriet Robinson, Ph. D., of the Emory Vaccine Center.
"It exposes your immune system to a pathogen like a virus or bacteria so before you've seen it you set up memory cells,” Dr. Robinson said, “and then these memory cells mobilize should you get the actual infection."
The test trials have been so successful that the vaccine is now more than a year ahead of schedule.
"Actually another two trials are starting later this year using different combinations of our vaccine and different administration programs,” said GeoVax CEO Hildebrand. “And following that presuming everything goes well we'll be starting a phase two program at the end of the year."
The vaccine works using a one-two pharmaceutical punch to prime the body then kill the virus.
“It raises both antibodies that can block the virus and it raises white blood cells called t cells that can kill the virus infected cells,” said Dr. Robinson. “So it really has two methods of controlling an HIV/AIDS infection once it enters the body."
The vaccine’s success with the simian AIDS virus has been nothing short of remarkable. Not only did the vaccine prevent the infection, it kept it under control for the monkeys that already had it, putting it in a kind of remission.
Researchers believe the same benefits await human subjects.
GOVX: HUGE>
AIDS Vaccine Nearing Reality at Emory (GOVX)
Keith Whitney reports
Emory University researchers working on a vaccine for the AIDS virus
Web Editor: Keith Whitney
Last Modified: 3/8/2007 7:49:17 AM
The world could have a new vaccine designed to kill the AIDS virus in as little as three to four years according to an Atlanta-based group working on the vaccine.
It is a scientific advance that could save tens of millions of lives, and it is being developed on the campus of Emory University.
The work has been going on quietly for the last 15 years. But now it appears headed for the bell lap in the race to prevent the disease.
And the Atlanta-based group may be way ahead of the rest of the world.
The GeoVax lab at Emory is smaller than many garages. And yet the small modular building may be where the battle to end the reign of one the world's biggest killers could be won with a vaccine to prevent AIDS.
"We're getting results back that indicate we're getting very strong immune responses in these individuals these people who received our vaccine," said Don Hildebrand, the president and CEO of GeoVax Inc., the company spearheading the research in collaboration with Emory, the Centers for Disease Control, and the National Institutes of Health.
The vaccine uses a decoy virus with some of the genetic material of the aids virus but not enough for anyone to ever get the disease itself from the shot, according to Dr. Harriet Robinson, Ph. D., of the Emory Vaccine Center.
"It exposes your immune system to a pathogen like a virus or bacteria so before you've seen it you set up memory cells,” Dr. Robinson said, “and then these memory cells mobilize should you get the actual infection."
The test trials have been so successful that the vaccine is now more than a year ahead of schedule.
"Actually another two trials are starting later this year using different combinations of our vaccine and different administration programs,” said GeoVax CEO Hildebrand. “And following that presuming everything goes well we'll be starting a phase two program at the end of the year."
The vaccine works using a one-two pharmaceutical punch to prime the body then kill the virus.
“It raises both antibodies that can block the virus and it raises white blood cells called t cells that can kill the virus infected cells,” said Dr. Robinson. “So it really has two methods of controlling an HIV/AIDS infection once it enters the body."
The vaccine’s success with the simian AIDS virus has been nothing short of remarkable. Not only did the vaccine prevent the infection, it kept it under control for the monkeys that already had it, putting it in a kind of remission.
Researchers believe the same benefits await human subjects.
Love it, Looks like a Davinchi. lol
Great day Thanx All!
GOVX HUGE Attention Coming.BREAKTHROUGH for HIV!
GOVX HUGE Attention Coming.BREAKTHROUGH for HIV!
GOVX HUGE Attention Coming.BREAKTHROUGH for HIV!
Looking SWEEEEEEEEEEEET!
QKBY UTing! .018 X .02
QKBY UTing! .018 X .02
This has not even left the gate yet. Yea Baby!
Is O/S Really only 10M?!
This looks like a good one!
QKBY Looks like it"s gonna be real good. R/M Coming!
QKBY Looks like it"s gonna be real good.
I Just must of got through on ST. Let her Rip.